At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
PF-04383119 +1 moredrug
Likely dose
PF-04383119 200 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED, PARALLEL GROUP PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04383119 FOR THE TREATMENT OF PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS
In Brief
A Phase 2 clinical trial evaluating PF-04383119 and Placebo for Cystitis, Interstitial. Completed, enrolled 65 participants across 34 sites.
Detailed Summary
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystitis, Interstitial
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartMar 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedJan 28, 2008
Enrollment StartMar 17, 2008
Primary CompletionApr 15, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.4 years ago
Interventions
PF-04383119drug
PF-04383119 200 mcg/kg IV, single dose
Placebodrug
placebo IV, single dose